Antiplatelet management US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Antiplatelet management. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Antiplatelet management US Medical PG Question 1: You are conducting a study comparing the efficacy of two different statin medications. Two groups are placed on different statin medications, statin A and statin B. Baseline LDL levels are drawn for each group and are subsequently measured every 3 months for 1 year. Average baseline LDL levels for each group were identical. The group receiving statin A exhibited an 11 mg/dL greater reduction in LDL in comparison to the statin B group. Your statistical analysis reports a p-value of 0.052. Which of the following best describes the meaning of this p-value?
- A. There is a 95% chance that the difference in reduction of LDL observed reflects a real difference between the two groups
- B. Though A is more effective than B, there is a 5% chance the difference in reduction of LDL between the two groups is due to chance
- C. If 100 permutations of this experiment were conducted, 5 of them would show similar results to those described above
- D. This is a statistically significant result
- E. There is a 5.2% chance of observing a difference in reduction of LDL of 11 mg/dL or greater even if the two medications have identical effects (Correct Answer)
Antiplatelet management Explanation: **There is a 5.2% chance of observing a difference in reduction of LDL of 11 mg/dL or greater even if the two medications have identical effects**
- The **p-value** represents the probability of observing results as extreme as, or more extreme than, the observed data, assuming the **null hypothesis** is true (i.e., there is no true difference between the groups).
- A p-value of 0.052 means there's approximately a **5.2% chance** that the observed 11 mg/dL difference (or a more substantial difference) occurred due to **random variation**, even if both statins were equally effective.
*There is a 95% chance that the difference in reduction of LDL observed reflects a real difference between the two groups*
- This statement is an incorrect interpretation of the p-value; it confuses the p-value with the **probability that the alternative hypothesis is true**.
- A p-value does not directly tell us the probability that the observed difference is "real" or due to the intervention being studied.
*Though A is more effective than B, there is a 5% chance the difference in reduction of LDL between the two groups is due to chance*
- This statement implies that Statin A is more effective, which cannot be concluded with a p-value of 0.052 if the significance level (alpha) was set at 0.05.
- While it's true there's a chance the difference is due to chance, claiming A is "more effective" based on this p-value before statistical significance is usually declared is misleading.
*If 100 permutations of this experiment were conducted, 5 of them would show similar results to those described above*
- This is an incorrect interpretation. The p-value does not predict the outcome of repeated experiments in this manner.
- It refers to the **probability under the null hypothesis in a single experiment**, not the frequency of results across multiple hypothetical repetitions.
*This is a statistically significant result*
- A p-value of 0.052 is generally considered **not statistically significant** if the conventional alpha level (significance level) is set at 0.05 (or 5%).
- For a result to be statistically significant at alpha = 0.05, the p-value must be **less than 0.05**.
Antiplatelet management US Medical PG Question 2: A 66-year-old woman presents to the emergency department complaining of palpitations. She says that she has been experiencing palpitations and lightheadedness for the past 6 months, but before this morning the episodes usually resolved on their own. The patient's medical history is significant for a transient ischemia attack 2 months ago, hypertension, and diabetes. She takes aspirin, metformin, and lisinopril. She states her grandfather died of a stroke, and her mom has a "blood disorder." An electrocardiogram is obtained that shows an irregularly irregular rhythm with rapid ventricular response, consistent with atrial fibrillation. She is given intravenous metoprolol, which resolves her symptoms. In addition to starting a beta-blocker for long-term management, the patient meets criteria for anticoagulation. Both unfractionated heparin and warfarin are started. Five days later, the patient begins complaining of pain and swelling of her left lower extremity. A Doppler ultrasound reveals thrombosis in her left popliteal and tibial veins. A complete blood count is obtained that shows a decrease in platelet count from 245,000/mm^3 to 90,000/mm^3. Coagulation studies are shown below:
Prothrombin time (PT): 15 seconds
Partial thromboplastin time (PTT): 37 seconds
Bleeding time: 14 minutes
Which of the following is the most likely diagnosis?
- A. Thrombotic thrombocytopenic purpura
- B. Type I heparin-induced thrombocytopenia
- C. Warfarin toxicity
- D. Idiopathic thrombocytopenia purpura
- E. Type II heparin-induced thrombocytopenia (Correct Answer)
Antiplatelet management Explanation: ***Type II heparin-induced thrombocytopenia***
- This diagnosis is strongly supported by the patient's **recent heparin exposure**, a significant **drop in platelet count** (from 245,000 to 90,000/mm^3, a >50% reduction), and new onset **thrombosis** (popliteal and tibial vein thrombosis).
- Type II HIT involves antibody formation against **heparin-platelet factor 4 (PF4) complexes**, leading to platelet activation, aggregation, and paradoxical thrombosis, often occurring 5-10 days after heparin initiation.
*Thrombotic thrombocytopenic purpura*
- While TTP involves microangiopathic hemolytic anemia, thrombocytopenia, and organ damage including neurological symptoms, the prompt onset of thrombosis after heparin strongly points away from TTP and towards **heparin-related complications**.
- This patient’s symptoms are primarily thrombotic, and typical TTP findings like **schistocytes on blood smear** and **severe ADAMTS13 deficiency** are not mentioned.
*Type I heparin-induced thrombocytopenia*
- Type I HIT is characterized by a **mild, non-immune-mediated platelet drop** (usually not below 100,000/mm^3) that occurs within the first 2 days of heparin therapy.
- It is **rarely associated with thrombosis**, which makes it an unlikely diagnosis given the severe platelet drop and new thromboses.
*Warfarin toxicity*
- Warfarin toxicity typically causes **bleeding complications** due to over-anticoagulation, rather than thrombosis, and is characterized by a **prolonged PT/INR**.
- Although the patient's bleeding time is prolonged, the thrombotic events and significant platelet drop point away from warfarin toxicity as the primary diagnosis.
*Idiopathic thrombocytopenia purpura*
- ITP is an autoimmune disorder causing **isolated thrombocytopenia** (often severe) and **bleeding**, but it is generally *not* associated with paradoxical thrombosis.
- The temporal relationship with heparin exposure and the thrombotic events are inconsistent with a primary diagnosis of unprovoked ITP.
Antiplatelet management US Medical PG Question 3: A 54-year-old man comes to the physician for a follow-up examination. One week ago, he was treated in the emergency department for chest pain, palpitations, and dyspnea. As part of his regimen, he was started on a medication that irreversibly inhibits the synthesis of thromboxane A2 and prostaglandins. Which of the following is the most likely adverse effect of this medication?
- A. Tinnitus
- B. Gout attack
- C. Chronic rhinosinusitis
- D. Acute interstitial nephritis
- E. Gastrointestinal hemorrhage (Correct Answer)
Antiplatelet management Explanation: ***Gastrointestinal hemorrhage***
- The medication described, which **irreversibly inhibits thromboxane A2 and prostaglandins**, is **aspirin**. Aspirin's inhibition of **prostaglandin synthesis** in the stomach reduces the protective mucous barrier, leading to an increased risk of **gastric ulcers** and **hemorrhage**.
- **Thromboxane A2 inhibition** by aspirin also impairs platelet aggregation, thereby increasing the risk of bleeding, including **gastrointestinal hemorrhage**.
- This is the **most common serious adverse effect** of chronic aspirin therapy, occurring in approximately 2-4% of patients on long-term low-dose aspirin for cardiovascular prophylaxis.
*Tinnitus*
- **Tinnitus** is a known adverse effect of **salicylate toxicity**, which usually occurs with higher doses of aspirin (>3-4 g/day). While possible, it's **uncommon with standard prophylactic doses** (81-325 mg/day) used for cardiovascular events.
- The question describes a regimen for a cardiac patient, implying a therapeutic dose rather than an overdose scenario.
*Gout attack*
- Aspirin's effect on **uric acid excretion** is dose-dependent: low doses (<1-2 g/day) can **decrease uric acid excretion**, potentially precipitating a gout attack, while high doses increase excretion.
- However, this effect is **less common** than GI complications, and aspirin is generally avoided in patients with known gout due to this complex effect and the availability of safer alternatives.
*Chronic rhinosinusitis*
- **Chronic rhinosinusitis** is not a direct adverse effect of aspirin. However, **aspirin-exacerbated respiratory disease (AERD)**, a condition involving asthma, nasal polyps, and chronic rhinosinusitis, can be triggered by aspirin in susceptible individuals.
- This is a **rare, specific syndrome** affecting approximately 7% of adults with asthma, not a general adverse effect for all patients on aspirin.
*Acute interstitial nephritis*
- **Acute interstitial nephritis** is more commonly associated with **non-steroidal anti-inflammatory drugs (NSAIDs)**, which also inhibit prostaglandin synthesis, but their effect on cyclooxygenase (COX) enzymes is typically reversible, unlike aspirin.
- While NSAIDs can cause AIN by acting as haptens and triggering an immune response, aspirin is **less frequently implicated** in this specific renal pathology compared to other NSAIDs.
Antiplatelet management US Medical PG Question 4: A primary care physician who focuses on treating elderly patients is researching recommendations for secondary prevention. She is particularly interested in recommendations regarding aspirin, as she has several patients who ask her if they should take it. Of the following, which patient should be started on lifelong aspirin as monotherapy for secondary prevention of atherosclerotic cardiovascular disease?
- A. An 83-year-old female with a history of a hemorrhagic stroke 1 year ago without residual deficits
- B. A 75-year-old male who had a drug-eluting coronary stent placed 3 days ago
- C. A 67-year-old female who has diabetes mellitus and atrial fibrillation
- D. A 45-year-old female with no health problems
- E. A 63-year-old male with a history of a transient ischemic attack (Correct Answer)
Antiplatelet management Explanation: **A 63-year-old male with a history of a transient ischemic attack**
- A patient with a history of **Transient Ischemic Attack (TIA)** has a high risk of subsequent stroke and should be on **lifelong aspirin monotherapy** for secondary prevention of **atherosclerotic cardiovascular disease (ASCVD)**.
- Aspirin helps prevent further thrombotic events by inhibiting platelet aggregation, making it a cornerstone for secondary prevention after TIA or ischemic stroke.
*An 83-year-old female with a history of a hemorrhagic stroke 1 year ago without residual deficits*
- Aspirin is generally **contraindicated** in patients with a history of **hemorrhagic stroke** due to the increased risk of recurrent bleeding.
- In such cases, the risks of aspirin therapy typically **outweigh the benefits** for cardiovascular prevention.
*A 75-year-old male who had a drug-eluting coronary stent placed 3 days ago*
- A patient with a recently placed **drug-eluting stent (DES)** requires **dual antiplatelet therapy (DAPT)**, typically aspirin plus a P2Y12 inhibitor, for a specific duration (e.g., 6-12 months), not aspirin monotherapy.
- Monotherapy with aspirin alone would be **insufficient** to prevent stent thrombosis in the immediate post-stenting period.
*A 67-year-old female who has diabetes mellitus and atrial fibrillation*
- This patient has two significant risk factors requiring specific management: **diabetes mellitus** for cardiovascular risk and **atrial fibrillation** for stroke risk.
- For atrial fibrillation, **anticoagulation with warfarin or a direct oral anticoagulant (DOAC)** is typically indicated, which makes aspirin monotherapy either unnecessary or potentially harmful if used alone.
*A 45-year-old female with no health problems*
- There is no indication for **aspirin primary prevention** in this patient, especially given the increased risk of bleeding without a clear cardiovascular benefit.
- Guidelines currently recommend against routine aspirin use for primary prevention in healthy individuals due to the **unfavorable risk-benefit ratio**.
Antiplatelet management US Medical PG Question 5: A 3-year-old male is evaluated for frequent nose bleeds. Physical examination shows diffuse petechiae on the patient's distal extremities. Peripheral blood smear shows an absence of platelet clumping. An ELISA binding assay reveals that platelet surfaces are deficient in GpIIb/IIIa receptors. Which of the following drugs pharmacologically mimics this condition?
- A. Clopidogrel
- B. Cilostazol
- C. Aspirin
- D. Abciximab (Correct Answer)
- E. Warfarin
Antiplatelet management Explanation: ***Abciximab***
- The patient exhibits symptoms of **Glanzmann thrombasthenia**, a genetic disorder characterized by a deficiency or qualitative defect of **glycoprotein IIb/IIIa (GpIIb/IIIa) receptors** on platelet surfaces, leading to impaired platelet aggregation. Abciximab is a **monoclonal antibody** that directly targets and inhibits the **GpIIb/IIIa receptor**, thus pharmacologically mimicking this condition.
- Abciximab binds to the **GpIIb/IIIa receptor** on activated platelets, preventing the binding of **fibrinogen** and **von Willebrand factor**, which are essential for platelet aggregation and thrombus formation.
*Clopidogrel*
- Clopidogrel is an **antiplatelet agent** that works by irreversibly blocking the **P2Y12 ADP receptor** on platelets, preventing **ADP-induced platelet activation** and aggregation.
- This mechanism is distinct from inhibiting the GpIIb/IIIa receptor directly and does not mimic Glanzmann thrombasthenia.
*Cilostazol*
- Cilostazol is a **phosphodiesterase-3 (PDE3) inhibitor** that increases **cyclic AMP (cAMP)** levels in platelets, leading to **reduced platelet aggregation** and **vasodilation**.
- Its mechanism of action is primarily related to inhibiting cAMP breakdown, which is different from GpIIb/IIIa receptor dysfunction.
*Aspirin*
- Aspirin is a **nonsteroidal anti-inflammatory drug (NSAID)** that irreversibly inhibits **cyclooxygenase-1 (COX-1)** in platelets, thereby reducing the production of **thromboxane A2 (TXA2)**.
- TXA2 is a potent platelet aggregator and vasoconstrictor. While aspirin is an antiplatelet agent, its mechanism does not involve the GpIIb/IIIa receptor.
*Warfarin*
- Warfarin is an **oral anticoagulant** that acts as a **vitamin K antagonist**, thereby inhibiting the synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X, and proteins C and S) in the liver.
- This drug affects the coagulation cascade rather than platelet function directly, and therefore does not mimic Glanzmann thrombasthenia.
Antiplatelet management US Medical PG Question 6: A 49-year-old man with a past medical history of hypertension on amlodipine presents to your office to discuss ways to lessen his risk of complications from heart disease. After a long discussion, he decides to significantly decrease his intake of trans fats in an attempt to lower his risk of coronary artery disease. Which type of prevention is this patient initiating?
- A. Secondary prevention
- B. Delayed prevention
- C. Quaternary prevention
- D. Tertiary prevention
- E. Primary prevention (Correct Answer)
Antiplatelet management Explanation: ***Primary prevention***
- This patient is initiating primary prevention by **modifying lifestyle choices** (decreasing trans fats) to **prevent the initial onset of coronary artery disease**, as he has a risk factor (hypertension) but no established heart disease.
- Primary prevention focuses on **preventing disease before it occurs** through health promotion and risk reduction.
*Secondary prevention*
- Secondary prevention involves **early detection and treatment of existing disease** to prevent progression or recurrence.
- Examples include **screening tests** like mammography or **medications for individuals already diagnosed** with a condition.
*Delayed prevention*
- This is **not a recognized category** of prevention in public health or medical practice.
- Prevention stages are typically classified as primary, secondary, tertiary, and sometimes quaternary.
*Quaternary prevention*
- Quaternary prevention aims to **protect patients from medical interventions** that may cause harm, such as over-medicalization or unnecessary procedures.
- It focuses on **reducing the burden of iatrogenic disease** and ensuring appropriate care.
*Tertiary prevention*
- Tertiary prevention focuses on **reducing the impact of an existing disease** or disability through rehabilitation and managing complications.
- It applies to patients who **already have an established disease** and seeks to improve their quality of life and functionality.
Antiplatelet management US Medical PG Question 7: A 70-year-old male presents for an annual exam. His past medical history is notable for shortness of breath when he sleeps, and upon exertion. Recently he has experienced dyspnea and lower extremity edema that seems to be worsening. Both of these symptoms have resolved since he was started on several medications and instructed to weigh himself daily. Which of the following is most likely a component of his medical management?
- A. Lidocaine
- B. Verapamil
- C. Carvedilol (Correct Answer)
- D. Aspirin
- E. Ibutilide
Antiplatelet management Explanation: ***Carvedilol***
- The patient exhibits classic symptoms of **heart failure**, such as **dyspnea on exertion**, **orthopnea** (shortness of breath when he sleeps), and **lower extremity edema**.
- **Beta-blockers** like carvedilol are essential for managing **chronic heart failure** by reducing myocardial oxygen demand and improving cardiac function.
*Lidocaine*
- **Lidocaine** is primarily an **antiarrhythmic drug** used for acute treatment of **ventricular arrhythmias**, not for chronic heart failure management.
- It works by blocking sodium channels and has no direct benefit in addressing the underlying pathophysiology of heart failure.
*Verapamil*
- **Verapamil** is a **non-dihydropyridine calcium channel blocker** typically used for hypertension, angina, and supraventricular tachyarrhythmias.
- It can have **negative inotropic effects**, which are generally contraindicated or used with extreme caution in patients with **systolic heart failure** due to its potential to worsen cardiac function.
*Aspirin*
- **Aspirin** is an **antiplatelet agent** used for primary or secondary prevention of **atherosclerotic cardiovascular disease** (e.g., in patients with coronary artery disease).
- It does not directly manage the symptoms or pathophysiology of **heart failure** unless there is a coexisting ischemic etiology.
*Ibutilide*
- **Ibutilide** is an **antiarrhythmic drug** specifically used for the rapid conversion of **atrial flutter and atrial fibrillation** of recent onset to sinus rhythm.
- It is not a medication used for the long-term management of **heart failure** symptoms described in the patient.
Antiplatelet management US Medical PG Question 8: A 70-year-old man with diabetes, hypertension, and chronic kidney disease (eGFR 35 mL/min/1.73m²) presents with NSTEMI. Troponin is elevated at 8.5 ng/mL. ECG shows 2mm ST depression in V2-V5. GRACE score is 165 (high risk). He is hemodynamically stable. Cardiologist recommends early invasive strategy within 24 hours. Nephrologist is concerned about contrast-induced nephropathy potentially requiring dialysis. Patient is on metformin. Evaluate the management strategy integrating multiple specialist perspectives and evidence.
- A. Proceed with angiography within 24 hours using iso-osmolar contrast and intravenous hydration, hold metformin (Correct Answer)
- B. Perform coronary CT angiography as alternative to invasive angiography
- C. Delay catheterization for 72 hours to optimize renal function with hydration
- D. Prophylactic hemodialysis before and after catheterization to remove contrast
- E. Medical management only with dual antiplatelet therapy, avoid catheterization
Antiplatelet management Explanation: ***Proceed with angiography within 24 hours using iso-osmolar contrast and intravenous hydration, hold metformin***
- High-risk NSTEMI patients with a **GRACE score >140** benefit from an **early invasive strategy** within 24 hours to reduce ischemic events and mortality.
- Renal protection is maximized through **pre-procedural hydration** and **iso-osmolar contrast**, while **metformin** must be held to avoid the risk of lactic acidosis if acute kidney injury occurs.
*Perform coronary CT angiography as alternative to invasive angiography*
- **Coronary CTA** is primarily used for ruling out coronary artery disease in low-to-intermediate risk stable patients, not for high-risk **NSTEMI**.
- This modality still requires **iodinated contrast** and does not provide the therapeutic benefit of percutaneous coronary intervention (**PCI**).
*Delay catheterization for 72 hours to optimize renal function with hydration*
- Delaying the procedure in a high-risk patient increases the risk of **re-infarction** and **cardiovascular death**, outweighing the minor benefits of prolonged hydration.
- Evidence suggests that optimization of renal status should happen concurrently with the preparation for **early intervention** in high-risk ACS.
*Prophylactic hemodialysis before and after catheterization to remove contrast*
- **Prophylactic hemodialysis** has not been proven to prevent contrast-induced nephropathy and may actually increase the risk of adverse events.
- High-volume **intravenous hydration** with isotonic saline remains the gold standard for preventing renal injury in patients with **CKD**.
*Medical management only with dual antiplatelet therapy, avoid catheterization*
- While **dual antiplatelet therapy** is essential, medical management alone is inferior to an invasive strategy in patients with **high GRACE scores**.
- Avoiding catheterization based solely on **renal impairment** results in "renalism," where patients are undertreated for their life-threatening cardiac condition.
Antiplatelet management US Medical PG Question 9: A 58-year-old woman with anterior STEMI underwent primary PCI with drug-eluting stent placement. Post-procedure echocardiogram shows left ventricular ejection fraction of 30% with apical akinesis. She is started on aspirin, ticagrelor, high-intensity statin, and ACE inhibitor. On hospital day 3, she develops atrial fibrillation with rapid ventricular response. CHA2DS2-VASc score is 4. Creatinine is normal. Evaluate the optimal antithrombotic strategy balancing ischemic and bleeding risk.
- A. Triple therapy with aspirin, ticagrelor, and apixaban indefinitely
- B. Triple therapy for 6 months, then aspirin and apixaban indefinitely
- C. Aspirin and ticagrelor only, hold anticoagulation due to bleeding risk
- D. Warfarin with INR 2-3 plus aspirin, discontinue ticagrelor
- E. Triple therapy for 1 month, then apixaban and clopidogrel for 11 months, then apixaban alone (Correct Answer)
Antiplatelet management Explanation: ***Triple therapy for 1 month, then apixaban and clopidogrel for 11 months, then apixaban alone***
- In patients with **Atrial Fibrillation** (CHA2DS2-VASc ≥2) undergoing **PCI**, current guidelines recommend minimizing the duration of **triple therapy** (aspirin, P2Y12 inhibitor, and anticoagulant) to 1 week to 1 month to reduce **bleeding risk**.
- Transitioning to **dual therapy** with a **NOAC** (like apixaban) and a P2Y12 inhibitor (preferably **clopidogrel**) for up to 12 months, followed by NOAC monotherapy, provides an optimal balance between preventing **stent thrombosis** and systemic **thromboembolism**.
*Triple therapy with aspirin, ticagrelor, and apixaban indefinitely*
- Indefinite **triple therapy** carries a prohibitively high risk of life-threatening **major bleeding** without added benefit for stroke prevention.
- **Ticagrelor** is generally avoided in triple therapy regimens due to a significantly higher bleeding profile compared to **clopidogrel**.
*Triple therapy for 6 months, then aspirin and apixaban indefinitely*
- **Triple therapy** for 6 months is rarely indicated and significantly increases the risk of **gastrointestinal and intracranial hemorrhage** compared to the 1-month strategy.
- Aspirin is usually discontinued after the first year in favor of **anticoagulant monotherapy**, as the latter is sufficient for both AF and stable CAD protection.
*Aspirin and ticagrelor only, hold anticoagulation due to bleeding risk*
- This approach leaves the patient with a high **CHA2DS2-VASc score of 4** unprotected against **cardioembolic stroke**, which carries high morbidity and mortality.
- Dual antiplatelet therapy (DAPT) alone is significantly less effective than **oral anticoagulants** for stroke prevention in the setting of atrial fibrillation.
*Warfarin with INR 2-3 plus aspirin, discontinue ticagrelor*
- **NOACs** (like apixaban) are now preferred over **Warfarin** for non-valvular AF due to a superior safety profile, including a lower risk of **intracranial hemorrhage**.
- Discontinuing the P2Y12 inhibitor (ticagrelor) immediately post-PCI in favor of aspirin and warfarin significantly increases the risk of **stent thrombosis**.
Antiplatelet management US Medical PG Question 10: A 60-year-old man with inferoposterior STEMI presents to a rural hospital. The nearest PCI-capable facility is 3 hours away. He arrives 90 minutes after symptom onset. Blood pressure is 130/85 mmHg, heart rate 88/min, oxygen saturation 96% on room air. He has no contraindications to fibrinolysis. The transfer team can arrive in 30 minutes. Evaluate the evidence-based approach considering time metrics and available resources.
- A. Immediate fibrinolytic therapy followed by transfer (Correct Answer)
- B. Helicopter transfer to reduce transfer time, then primary PCI
- C. Administer half-dose fibrinolytic and transfer for immediate PCI
- D. Fibrinolytic therapy at rural hospital, transfer only if fails
- E. Wait for transfer team and proceed directly to PCI facility
Antiplatelet management Explanation: ***Immediate fibrinolytic therapy followed by transfer***
- In a STEMI patient where the expected **door-to-balloon time** exceeds **120 minutes**, and the patient is seen within **12 hours** of symptom onset, **fibrinolytic therapy** is the preferred reperfusion strategy.
- Following fibrinolysis, a **pharmacoinvasive strategy** is recommended, involving a routine transfer to a PCI-capable center for angiography within **3 to 24 hours**.
*Helicopter transfer to reduce transfer time, then primary PCI*
- Even with expedited transport, the distance and total time likely still exceed the recommended **120-minute window** for primary PCI superiority over fibrinolysis.
- Choosing transfer over immediate thrombolysis in a rural setting when delays are significant increases the risk of **myocardial necrosis**.
*Administer half-dose fibrinolytic and transfer for immediate PCI*
- **Half-dose fibrinolytics** are generally only considered in specific subsets like elderly patients (over 75) to reduce **intracranial hemorrhage** risk, which does not apply here.
- Combining half-dose thrombolysis with immediate PCI (facilitated PCI) has not shown superior outcomes and may increase **bleeding complications**.
*Fibrinolytic therapy at rural hospital, transfer only if fails*
- Modern guidelines recommend a **pharmacoinvasive approach**, meaning all patients should be transferred for **coronary angiography** regardless of clinical success of fibrinolysis.
- Waiting only for "failure" (rescue PCI) ignores the benefit of definitive **revascularization** and stabilization provided by routine post-thrombolysis PCI.
*Wait for transfer team and proceed directly to PCI facility*
- Delaying reperfusion for a 3-hour transport window violates the "**time is muscle**" principle, as the patient is currently in the highly time-sensitive **early window** (under 3 hours).
- Failure to administer fibrinolytics when the **PCI-related delay** is over 90-120 minutes is a deviation from standard **STEMI management protocols**.
More Antiplatelet management US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
